Rachit Manchanda, Hardik Doshi, M M Rekha, G Nancy Priscilla, Rajashree Panigrahi, Jayant Jagtap, Abhijit Bhowmik, Rupesh Gupta, Jigna Prajapati, Biswajit Basu
{"title":"Machine Learning for Targeted Nano Medicine in Parkinson's Disease: A Data-Driven Approach for Diagnosis and Treatment.","authors":"Rachit Manchanda, Hardik Doshi, M M Rekha, G Nancy Priscilla, Rajashree Panigrahi, Jayant Jagtap, Abhijit Bhowmik, Rupesh Gupta, Jigna Prajapati, Biswajit Basu","doi":"10.2174/0115680266418706260310070233","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Parkinson's Disease (PD) is a progressive neurodegenerative disorder that impairs motor and cognitive functioning, making early diagnosis and patient-specific treatment essential; however, traditional clinical assessments often delay detection and lack consistency.</p><p><strong>Methods: </strong>This paper proposes TriFusion-PD, a multimodal Machine-Learning-Driven Targeted Nanomedicine (ML-TN) framework designed to improve early PD diagnosis and personalized therapy. The methodology integrates Transformers for analyzing temporal voice and speech patterns, Convolutional Neural Networks (CNNs) for extracting spatial biomarkers from MRI and spiral-drawing images, and Reinforcement Learning (RL) for optimizing individualized treatment recommendations. Three publicly available datasets-voice recordings, speech-signal features, and drawing/imaging data-were pre-processed, feature-engineered, and evaluated through a unified ML pipeline using metrics such as accuracy, precision, recall, F1-score, Matthews Correlation Coefficient (MCC), robustness, computational efficiency, and ROC-AUC.</p><p><strong>Results: </strong>The findings show that TriFusion-PD significantly outperforms baseline models including CNN, SVM-KNN, XGBoost, LSTM, and Random Forest, achieving up to 12.5% higher accuracy, 14.2% higher precision, 15.0% higher recall, and 13.8% higher F1-score, with the highest improvement observed in MCC (16.4%), indicating more balanced and reliable PD classification across modalities.</p><p><strong>Discussion: </strong>These performance gains arise from the complementary strengths of multimodal fusion, which enhances sensitivity to subtle PD symptoms, while RL-based optimization reduces misclassification and improves predictive stability under noisy or incomplete data conditions.</p><p><strong>Conclusion: </strong>Overall, TriFusion-PD presents a robust and clinically relevant data-driven solution for early PD detection and personalized treatment planning, demonstrating strong potential for integration into next-generation clinical decision-support systems.</p>","PeriodicalId":11076,"journal":{"name":"Current topics in medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680266418706260310070233","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Parkinson's Disease (PD) is a progressive neurodegenerative disorder that impairs motor and cognitive functioning, making early diagnosis and patient-specific treatment essential; however, traditional clinical assessments often delay detection and lack consistency.
Methods: This paper proposes TriFusion-PD, a multimodal Machine-Learning-Driven Targeted Nanomedicine (ML-TN) framework designed to improve early PD diagnosis and personalized therapy. The methodology integrates Transformers for analyzing temporal voice and speech patterns, Convolutional Neural Networks (CNNs) for extracting spatial biomarkers from MRI and spiral-drawing images, and Reinforcement Learning (RL) for optimizing individualized treatment recommendations. Three publicly available datasets-voice recordings, speech-signal features, and drawing/imaging data-were pre-processed, feature-engineered, and evaluated through a unified ML pipeline using metrics such as accuracy, precision, recall, F1-score, Matthews Correlation Coefficient (MCC), robustness, computational efficiency, and ROC-AUC.
Results: The findings show that TriFusion-PD significantly outperforms baseline models including CNN, SVM-KNN, XGBoost, LSTM, and Random Forest, achieving up to 12.5% higher accuracy, 14.2% higher precision, 15.0% higher recall, and 13.8% higher F1-score, with the highest improvement observed in MCC (16.4%), indicating more balanced and reliable PD classification across modalities.
Discussion: These performance gains arise from the complementary strengths of multimodal fusion, which enhances sensitivity to subtle PD symptoms, while RL-based optimization reduces misclassification and improves predictive stability under noisy or incomplete data conditions.
Conclusion: Overall, TriFusion-PD presents a robust and clinically relevant data-driven solution for early PD detection and personalized treatment planning, demonstrating strong potential for integration into next-generation clinical decision-support systems.
期刊介绍:
Current Topics in Medicinal Chemistry is a forum for the review of areas of keen and topical interest to medicinal chemists and others in the allied disciplines. Each issue is solely devoted to a specific topic, containing six to nine reviews, which provide the reader a comprehensive survey of that area. A Guest Editor who is an expert in the topic under review, will assemble each issue. The scope of Current Topics in Medicinal Chemistry will cover all areas of medicinal chemistry, including current developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, and structure-activity relationships. Medicinal chemistry is a rapidly maturing discipline. The study of how structure and function are related is absolutely essential to understanding the molecular basis of life. Current Topics in Medicinal Chemistry aims to contribute to the growth of scientific knowledge and insight, and facilitate the discovery and development of new therapeutic agents to treat debilitating human disorders. The journal is essential for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important advances.